4013-94-9

Basic information

• Product Name: N,N'-Diisopropylethylenediamine
• Synonyms: 1,2-Ethanediamine, N,N'-bis(1-methylethyl)-;n,n’-bis(1-methylethyl)-2-ethanediamine;N,N'-Disopropylethylene diamine;1,2-BIS-(ISOPROPYLAMINO)-ETHANE;N,N'-Diisopropylethylendiamine;N,N'-Diisopropylethylenediamine,97%;N,N''-DIISOPYLETHYEND DIAMINE;N,N'-Diisopropylethylenediamine
• CAS NO: 4013-94-9
• Molecular Formula: C₈H₂₀N₂
• Molecular Weight: 144.26
• EINECS: 223-666-6
• Product Categories: Amine Monomers;Monomers;Secondary Amines
• Mol File: 4013-94-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 52°C (estimate)
• Boiling Point: 169-171 °C(lit.)
• Flash Point: 125 °F
• Appearance: clear colorless liquid
• Density: 0.798 g/mL at 25 °C(lit.)
• Refractive Index: n20/D 1.4289(lit.)
• PKA: 10.46±0.29(Predicted)
• Water Solubility: Miscible with water.
• Sensitive: Hygroscopic
• BRN: 1735571
• CAS DataBase Reference: N,N'-Diisopropylethylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-Diisopropylethylenediamine(4013-94-9)
• EPA Substance Registry System: N,N'-Diisopropylethylenediamine(4013-94-9)

Safety Data

• Hazard Codes: C
• Statements: 10-34
• Safety Statements: 16-26-27-36/37/39-45-25
• RIDADR: UN 2733 3/PG 3
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 3
• PackingGroup: III
• Hazardous Substances Data: 4013-94-9(Hazardous Substances Data)

Usage

Chemical Properties

clear colorless liquid

Uses

N,N'-Diethylethylenediamine is used in the preparation of 2-imidazolidinecarboxaldehydes and 1,4,6,9-tetraalkyl-1,4,6,9-tetraaza-5,10-dioxaperhydroanthracenes by reacting with glyoxal. It acts as a ligand and form coordination complexes with copper(II), which shows thermochromic properties.

Upstream product

• 75-31-0 isopropylamine 
• 107-06-2 1,2-dichloro-ethane 
• 106-93-4 ethylene dibromide 
• 107-15-3 ethylenediamine 
• 67-64-1 acetone 
• 75-26-3 isopropyl bromide 
• 24764-90-7 N,N'-diisopropyl-1,4-diaza-1,3-butadiene 
• 226068-74-2 N,N'-dibenzyl-N,N'-diisopropylethylenediamine 

Downstream Products

• 54966-00-6 N,N'-diisopropyl N,N'-dimethyl-1,2-ethanediamine 
• 129920-20-3 1,3-diisopropyl-2-methyl-1,3,2-diazaborolidine 
• 7550-35-8 lithium bromide 
• 1439937-79-7 3-benzyl-3-(trifluoromethyl)-1,4-diisopropylpiperazin-2-one 
• 1335231-37-2 GeCl(2,6-iPr₂C₆H₃NC₇H₈P(C₂H₄N₂(iPr)2)) 
• 1550176-73-2 N-(5-((isopropyl(2-(isopropylamino)ethyl)amino)methyl)-2-methylphenyl)-4-((5-methyl-4-(4-(trifluoromethoxy)phenyl)pyrimidin-2-yl)amino)benzamide 
• 1441135-90-5 C₂₆H₃₃BN₂Pb 
• 1441135-85-8 C₂₆H₃₃BN₂Sn 
• 1441135-80-3 C₂₆H₃₃BN₂Si 
• 217455-53-3 [Cu(acetylacetonate)(N,N'-diisopropylethylenediamine)]BPh₄ 
• 554-68-7 triethylamine hydrochloride 
• 92527-11-2 2-chloro-1,3-diisopropyl-1,3,2-diazaborolidine 
• 116907-13-2 risotilide hydrochloride 

Relevant articles and documents

Experimental and Theoretical Study of an Intramolecular CF3-Group Shift in the Reactions of α-Bromoenones with 1,2-Diamines

The reactions of trifluoromethylated 2-bromoenones and N,N′-dialkyl-1,2-diamines have been studied. Depending on the structures of the starting compounds, the formation of 2-trifluoroacetylpiperazine or 3-trifluoromethylpiperazine-2-ones was observed. The mechanism of the reaction is discussed in terms of multistep processes involving sequential substitution of bromine in the starting α-bromoenones and intramolecular cyclization of the captodative aminoenones as key intermediates to form the target heterocycles. The results of theoretical calculations are in perfect agreement with the experimental data. The unique role of the trifluoromethyl group in this reaction is demonstrated.

SATURATED N-HETEROCYCLIC CARBENE-LIGAND METAL COMPLEX DERIVATIVES, PREPARING METHOD THEREOF, AND PREPARING METHOD OF SILANE COMPOUND BY HYDROSILYLATION REACTION USING THE SAME AS CATALYST

Provided are a saturated N-heterocyclic carbene-ligand metal complex derivative, a method for preparing the same, and a method for preparing a silane compound by hydrosilylation using the same as a catalyst. To describe in more detail, the metal complex derivative has a saturated N-heterocyclic carbene derivative and an olefin ligand at the same time. A silane compound is prepared by hydrosilylation in the presence of the metal complex derivative as a catalyst. The provided metal complex derivative of the present invention has superior stability during hydrosilylation reaction and is capable of effectively performing the hydrosilylation reaction at low temperature even with small quantity. Further, a product with superior regioselectivity may be obtained. In addition, after the hydrosilylation reaction is completed, the metal complex derivative may be recovered and recycled.

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type ii diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'- dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline

Piperazine derivatives have been identified as new antidiabetic compounds. Structure-activity relationship studies in a series of 1-benzyl- 4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines resulted in the identification of 1-methyl-4-(2',4'-dichlorobenzyl)-2-(4',5'-dihydro-1'H- imidazol-2'-yl)piperazine, PMS 812 (S-21663), as a highly potent antidiabetic agent on a rat model of diabetes, mediated by an important increase of insulin secretion independently of α2 adrenoceptor blockage. These studies were extended to find additional compounds in these series with improved properties. In such a way, substitution of both piperazine N atoms was first optimized by using various alkyl, branched or not, and benzyl groups. Second, some modifications of the imidazoline ring and its replacement by isosteric heterocycles were carried out, proceeding from PMS 812, to evaluate their influence on the antidiabetic activity. The importance of the distance between the imidazoline ring and the piperazine skeleton was studied third. Finally, the influence of the N-benzyl moiety was also analyzed compared to a direct N-phenyl substitution. The pharmacological evaluation was performed in vivo using glucose tolerance tests on a rat model of type II diabetes. The most active compounds were 1,4-diisopropyl-2-(4',5'-dihydro-1'H-imidazol-2'- yl)piperazine (41a), PMS 847 (S-22068), and 1,4-diisobutyl-2-(4',5'-dihydro- 1'H-imidazol-2'-yl)piperazine (41b), PMS 889 (S-22575), which strongly improved glucose tolerance without any side event or hypoglycemic effect. More particularly, PMS 847 proved to be as potent after po (100 μmol/kg) as after ip administration and appears as a good candidate for clinical investigations.